BidaskClub upgraded shares of Ziopharm Oncology (NASDAQ:ZIOP) from a strong sell rating to a sell rating in a research report released on Wednesday.
A number of other analysts have also issued reports on the company. Zacks Investment Research lowered Ziopharm Oncology from a hold rating to a sell rating in a research report on Thursday, March 15th. HC Wainwright set a $10.00 target price on Ziopharm Oncology and gave the stock a buy rating in a research report on Monday, March 5th. ValuEngine lowered Ziopharm Oncology from a sell rating to a strong sell rating in a research report on Thursday, March 1st. Finally, Raymond James Financial reaffirmed a hold rating on shares of Ziopharm Oncology in a research report on Monday, December 11th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and one has given a buy rating to the company. Ziopharm Oncology currently has an average rating of Hold and a consensus price target of $7.50.
NASDAQ:ZIOP opened at $4.32 on Wednesday. Ziopharm Oncology has a 12 month low of $3.33 and a 12 month high of $7.88. The stock has a market capitalization of $619.43, a price-to-earnings ratio of -8.15 and a beta of 1.72.
Ziopharm Oncology (NASDAQ:ZIOP) last announced its earnings results on Thursday, March 1st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.13). The business had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.59 million. During the same period in the previous year, the firm posted ($0.11) earnings per share. The firm’s revenue was up .0% compared to the same quarter last year. equities research analysts anticipate that Ziopharm Oncology will post -0.53 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of Ziopharm Oncology by 3.4% during the fourth quarter. BlackRock Inc. now owns 8,499,209 shares of the biotechnology company’s stock worth $35,187,000 after acquiring an additional 280,003 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Ziopharm Oncology by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 1,160,653 shares of the biotechnology company’s stock worth $4,805,000 after acquiring an additional 22,575 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Ziopharm Oncology by 4.2% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 644,642 shares of the biotechnology company’s stock worth $2,669,000 after acquiring an additional 26,053 shares during the last quarter. Deutsche Bank AG grew its stake in Ziopharm Oncology by 141.1% in the fourth quarter. Deutsche Bank AG now owns 294,287 shares of the biotechnology company’s stock worth $1,216,000 after purchasing an additional 172,227 shares in the last quarter. Finally, Vident Investment Advisory LLC grew its stake in Ziopharm Oncology by 38.8% in the fourth quarter. Vident Investment Advisory LLC now owns 293,082 shares of the biotechnology company’s stock worth $1,213,000 after purchasing an additional 81,940 shares in the last quarter. 40.15% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Ziopharm Oncology (ZIOP) Raised to Sell at BidaskClub” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/ziopharm-oncology-ziop-raised-to-sell-at-bidaskclub.html.
About Ziopharm Oncology
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
Receive News & Ratings for Ziopharm Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology and related companies with MarketBeat.com's FREE daily email newsletter.